Medtronic releases 1-year hypertension ablation study | On Call

Tue, 12/25/2012 - 7:29am
Mass Device

Medical device giant Medtronic releases 1-year results from its Symplicity HTN-2 trial of renal ablation as treatment for drug-resistant hypertension.

MassDevice On Call

MASSDEVICE ON CALL — Renal ablation continues to look good as a treatment for drug-resistant hypertension after 1 year of follow-up, according to newly released results of Medtronic's (NYSE:MDT) Symplicity HTN-2 trial.

Researchers directed "short bursts of radio waves" at the nerves surrounding the kidneys, successfully lowering blood pressure for at least 6 months and up to 1 year, according to the American Heart Assn.

"Studies will soon determine whether this procedure can cure mild hypertension, producing permanent drug-free normalization of blood pressure," Murray Esler, professor and senior director of the Baker IDI Heart & Diabetes Institute in Australia, said in prepared remarks. "Based on the blood pressure declines achieved, reduction in heart attack and stroke rates of more than 40 percent is anticipated."


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.